SCHEMBL3356515

SCHEMBL3356515

O=C(O)N(O)CCCNCc1ccccc1OC(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
CHRM2 P08172 11/20 0.43
BCHE P06276 6/20 0.43
ACHE P22303 6/20 0.43
SLC40A1 Q9NP59 1/20 0.42
PPARG P37231 1/20 0.41
GRIN1 Q05586 4/20 0.41
GRIN2A Q12879 4/20 0.41
TP53 P04637 1/20 0.41
CHRM4 P08173 1/20 0.41
CYP3A4 P08684 1/20 0.41
CHRM5 P08912 1/20 0.41
CYP2D6 P10635 1/20 0.41
CHRM1 P11229 1/20 0.41
TSHR P16473 1/20 0.41
CHRM3 P20309 1/20 0.41
THPO P40225 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3350267 0.78 SCN8A (0.50) PPARG
SCHEMBL3352542 0.77 CHRM2 (0.58) CHRM2TP53TSHRKMT2A
SCHEMBL3351531 0.76 MAPK14 (0.50) CHRM2BCHEKMT2A
SCHEMBL10231709 0.76 CHRM2 (0.47) HDAC3HDAC1HDAC2HDAC6CHRM2
SCHEMBL9903529 0.76 CHRM2 (0.52) HDAC3HDAC1HDAC2HDAC6CHRM2
SCHEMBL16269347 0.75 CHRM2 (0.48) CHRM2BCHEACHEGRIN1GRIN2A
SCHEMBL25590514 0.74 CHRM2 (0.57) CHRM2BCHEACHEGRIN1GRIN2A
Toluene SCHEMBL3909886 0.73 CHRM2 (0.54) CHRM2TP53TSHRKMT2A
SCHEMBL9882920 0.73 SIGMAR1 (0.50) HDAC3HDAC1HDAC2HDAC6CHRM2
SCHEMBL9903526 0.72 HDAC3 (0.50) HDAC3HDAC1HDAC2HDAC6PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP HDAC3 527/4885HDAC1 426/4885HDAC2 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.